Efficacy and safety of different drugs in patients with HER2-positive gastric cancer: network meta-analysis

被引：0
作者：
Zhang, Jie [1 ,2 ]
Yuan, Chunluan [1 ]
Ma, Xiao [2 ]
机构：
[1] First Peoples Hosp Lianyungang, Dept Oncol, Lianyungang 222000, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 2, Dept Oncol, Nanjing 210008, Jiangsu, Peoples R China
来源：
SYSTEMATIC REVIEWS | 2025年 / 14卷 / 01期
关键词：
Gastric cancer; Network meta-analysis; Efficacy; Safety; GASTROESOPHAGEAL JUNCTION; TRASTUZUMAB EMTANSINE; OPEN-LABEL; PLUS CHEMOTHERAPY; DOUBLE-BLIND; ESOPHAGEAL; DERUXTECAN; LAPATINIB; NIVOLUMAB; TAXANE;
D O I：
10.1186/s13643-025-02777-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BackgroundIn the past decade, there has been a significant advancement in targeted therapy and immunotherapy, leading to the discovery of new drugs and changes in the treatment approach for patients with HER2-positive gastric cancer. Although several drugs are available for treating these patients, there is still no consensus on their selection, and there has been limited direct or indirect comparison among them.ObjectiveTo address this gap, a network meta-analysis was conducted to assess the efficacy and safety of different drugs used in the treatment of HER2-positive gastric cancer.MethodsBy searching through databases such as PubMed, Embase, Web of Science, and Cochrane Library, we identified 16 randomized controlled trials that involved a total of 4485 patients and utilized 9 different intervention measures.ResultsBased on the current evidence, compared with chemotherapy alone, the hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) in gastric cancer patients treated with nivolumab were [hazard ratio (HR): 2.61 95%confidence interval (CI) (1.51, 4.51)] and [hazard ratio (HR): 2.01 95% confidence interval (CI) (1.18, 3.42)], respectively. Compared with chemotherapy alone, the hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) in gastric cancer patients treated with trastuzumab deruxtecan were [hazard ratio (HR): 1.7 95% confidence interval (CI) (1.13, 2.56)] and [hazard ratio (HR): 2.13 95% confidence interval (CI) (1.42, 3.22)], respectively. It is suggested that nivolumab and trastuzumab deruxtecan can effectively prolong overall survival (OS) and progression-free survival(PFS) in patients with HER2-positive gastric cancer, while also reducing the risk of adverse events to some extent. Therefore, these two regimens, nivolumab and trastuzumab deruxtecan, are considered to be effective and safe options for the treatment of patients with HER2-positive gastric cancer.ConclusionsIn previous studies, trastuzumab-based chemotherapy has been a common treatment for HER2-positive gastric cancer. To a certain extent, our study provides a reliable direction for future treatment options for HER2-positive gastric cancer.Systematic review registrationPROSPERO CRD42023420941
引用
收藏
页数：13
相关论文
共 48 条
  • [1] Lin Y., Zheng Y., Wang H.L., Wu J., Global patterns and trends in gastric cancer incidence rates (1988–2012) and Predictions to 2030, Gastroenterology, 161, pp. 116-127, (2021)
  • [2] Hamashima C., Systematic Review G Guideline Development Group for Gastric Cancer Screening, G. Update version of the Japanese Guidelines for Gastric Cancer Screening, Jpn J Clin Oncol, 48, pp. 673-683, (2018)
  • [3] Ricci A.D., Rizzo A., Brandi G., DNA damage response alterations in gastric cancer: knocking down a new wall, Future Oncol, 17, pp. 865-868, (2021)
  • [4] Dall'Olio F.G., Rizzo A., Mollica V., Massucci M., Maggio I., Massari F., Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis, Immunotherapy, 13, pp. 257-270, (2021)
  • [5] Tsimberidou A.M., Fountzilas E., Nikanjam M., Kurzrock R., Review of precision cancer medicine: Evolution of the treatment paradigm, Cancer Treat Rev, 86, (2020)
  • [6] Sun J., Li X., Chen P., Gao Y., From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer, J Inflamm Res, 15, pp. 4061-4085, (2022)
  • [7] Keam S.J., Trastuzumab deruxtecan: first approval, Drugs, 80, pp. 501-508, (2020)
  • [8] Cortes J., Kim S.B., Chung W.P., Im S.A., Park Y.H., Hegg R., Kim M.H., Tseng L.M., Petry V., Chung C.F., Et al., Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer, N Engl J Med, 386, pp. 1143-1154, (2022)
  • [9] Xue C., Xu Y.H., Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial, Medicine (Baltimore), 101, (2022)
  • [10] Abuhelwa Z., Alloghbi A., Alqahtani A., Nagasaka M., Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review, Drugs, 82, pp. 979-987, (2022)
12345